Pubblicazioni

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration

2022 - LEUKEMIA

Cappelli, L. V.; Meggendorfer, M.; Baer, C.; Nadarajah, N.; Hutter, S.; Jeromin, S.; Dicker, F.; Kern, W.; Haferlach, T.; Haferlach, C.; Hollein, A.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

2015 - ANNALS OF HEMATOLOGY

Oosterveld, M; Suciu, S; Muus, P; Germing, U; Delforge, M; Belhabri, A; Aul, C; Selleslag, D; Ferrant, A; Marie, Jp; Amadori, S; Jehn, U; Mandelli, F; Hess, U; HellstrÃ¶m-Lindberg, E; Cakmak-Wollgast, S; Vignetti, M; Labar, B; Willemze, R; de Witte, T.